GlassScriptPhysician profile
Joseph Giardina
NPI 1992004527
$31,978.79
in general payments reported to CMS, 2019-2025
9 companies · $3,777 in 2025
The $3,777 reported for 2025 was more than what 83% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $16K · 2021: $866 · 2022: $10K · 2023: $298 · 2024: $483 · 2025: $3,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,738 · Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,737.50 |
| Food and Beverage | $820.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17,454.07 | 2020-2025 | General - Embolics, General - Io Ablation, Spyscope Ds |
| Terumo Medical Corporation | $7,361.50 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $3,936.55 | 2024-2025 | |
| Trisalus Life Sciences, INC. | $1,993.49 | 2021-2022 | |
| Sirtex Medical INC | $869.88 | 2021-2024 | Sir-Spheres Microspheres |
| Galvanize Therapeutics, INC | $168.47 | 2023 | Aliya System |
| Biocompatibles, INC. | $98.41 | 2019 | |
| Medtronic Vascular, INC. | $71.96 | 2019 | |
| Inari Medical, INC. | $24.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Giardina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.